Intuitive Surgical stock slips as volatility outpaces returns

Intuitive Surgical stock traded at 401.58 euros on Lang & Schwarz at 16:41 CET on Tuesday, November 10, 2026. That was 2.23 percent below the 410.75-euro quote in the latest report published earlier the same day, a separate report-to-report comparison rather than a Xetra daily comparison.

Returns lagged despite wider swings

In an analysis published on Tuesday, November 10, Trefis compared Intuitive Surgical with the S&P 500 over the five years through November 9. The company delivered an annual return of 5.3 percent, versus 11.9 percent for the index, while annual volatility reached 34.9 percent compared with 17.1 percent.

The analysis calculated a return-to-volatility ratio of 0.152 for Intuitive Surgical against 0.696 for the S&P 500. Over the past year, the stock's volatility was 35.6 percent, while its correlation with the index was 0.36, indicating that company-specific factors contributed materially to its swings.

Pricing and legal costs remain

Management expects pricing actions, including a policy-driven price cut in China, to reduce da Vinci instrument and accessory revenue per procedure by 3 percent to 5 percent once fully implemented, assuming procedure volume and product mix remain unchanged.

Intuitive Surgical has also agreed to a 450 million US dollar settlement in a US customer class action involving third-party remanufacturing of da Vinci instruments and third-party servicing of da Vinci systems. Court approval remains pending, with a decision not expected until 2027, according to the Trefis analysis.

January brings the next test

Management is expected to update its estimate of the long-term soft-tissue surgery opportunity when Intuitive Surgical reports in January 2027. US da Vinci procedure growth will remain a central operating indicator, particularly as investors assess pricing, legal costs and demand outside the United States.

The S&P 500 provides the broader US equity-market context for assessing the stock's relative performance.

More news and analyses on Intuitive Surgical stock